JDRF is soliciting letters of intent (LOI) for the discovery, development and pre-clinical testing of tolerogenic delivery systems (TDS) of diabetes-specific autoantigens designed to prevent and/or reverse type 1 diabetes (T1D). JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential.
This initiative encourages collaborations between experts in the fields of bioengineering, immune tolerance, and T1D. However, investigators with assays or hypotheses relevant to this initiative are welcomed to apply.
Funding & Duration
Up to a maximum of US $250,000 per year (approx. AUD $226,000 – including 10% indirect costs) for up to 2 years may be requested.
Applications may be submitted by domestic and foreign for profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government.
Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
For clinical studies, applicants must hold an appointment or joint appointment in a sub-specialty of clinical medicine, and conduct human clinical research.
There are no citizenship requirements for this program.
Submission Requirements & Due Dates
- 3 December 2015 – Letter of Intent (LOI) via RMS360
- Copy of LOI forwarded to the Research Branch ASAP.
- 24 February 2016 – full applications submitted to the Research Branch for internal review.
Grants Officer: Dr Don McMaster